1.Gastrointestinal Distress: Very common and often severe (Nausea, Vomiting, Diarrhea, Constipation, Abdominal Pain). Can be debilitating and impede training/nutrition. Tolerance often develops slowly.
2.Muscle Loss Risk: Despite relative preservation, significant absolute muscle loss is still highly likely, especially if protein intake and training volume/intensity aren't meticulously maintained. Glucagon can have catabolic effects on muscle protein under certain conditions.
3.Hypoglycemia Risk: Especially when combined with insulin or insulin secretagogues, or during intense calorie restriction and training. Glucagon agonism complicates glucose management.
4.Tachyphylaxis: Effectiveness may wane over time, requiring dose increases for the same effect, potentially amplifying side effects.
5.Pancreatitis Risk: A known (though rare) risk with GLP-1 agonists; dual agonism's impact is unknown.
6.Gallbladder Issues: Increased risk of gallstones observed with GLP-1 agonists.
7.Thyroid C-Cell Tumor Risk: Seen in rodent studies with GLP-1 agonists; human relevance is unclear but a black box warning exists for some. Mazdutide's impact is unknown.
8.Cardiovascular Effects: Long-term CV effects in healthy individuals are unknown. Potential for increased heart rate.
9.Unregulated Supply: Sourcing involves research chemicals or grey-market peptides with risks of contamination, incorrect dosing, and counterfeit products.
10.Lack of Long-Term Data: Safety and efficacy profiles for long-term use or in healthy, athletic populations are completely unknown.
11.Cost: Can be prohibitively expensive.






